We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+49.01%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.43B
AUM Growth
-$263M
Cap. Flow
-$141M
Cap. Flow %
-9.8%
Top 10 Hldgs %
54.7%
Holding
66
New
3
Increased
9
Reduced
40
Closed
4
Avg Time Held
3.4 years
Top 10 Avg Time Held
1.7 years
Top 20 Avg Time Held
1.5 years

Top Buys

Rank Stock Value
1
NGNE icon
Neurogene
NGNE
+$13.2M
2
CBLL icon
CeriBell Inc
CBLL
+$11.9M
3
RAPT icon
RAPT Therapeutics
RAPT
+$9.48M
4
LIVN icon
LivaNova
LIVN
+$8.64M
5
SLN icon
Silence Therapeutics
SLN
+$6.45M

Top Sells

Rank Stock Value
1
AUGX icon
Augmedix, Inc. Common Stock
AUGX
+$38.5M
2
CTLT icon
CATALENT, INC.
CTLT
+$36.1M
3
SRRK icon
Scholar Rock
SRRK
+$22.4M
4
KYMR icon
Kymera Therapeutics
KYMR
+$13.2M
5
FOLD icon
Amicus Therapeutics
FOLD
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RPTX icon
51
DELISTED
Repare Therapeutics
RPTX
$2.51M 0.17%
1,916,089
-26,466
-1% -$78.8K
2020 Q2
18 quarters
PODD icon
52
Insulet
PODD
$9.62B
$2.5M 0.17%
+9,559
New +$2.41M
2024 Q4
0 quarters
SLDB icon
53
Solid Biosciences
SLDB
$615M
$2.46M 0.17%
+615,246
New +$3.38M
2024 Q4
0 quarters
BOLD icon
54
Boundless Bio
BOLD
$54.3M
$2.15M 0.15%
740,204
-283,344
-28% -$826K
2024 Q1
3 quarters
LVTX icon
55
DELISTED
LAVA Therapeutics
LVTX
$1.97M 0.14%
2,074,372
– –
2021 Q1
15 quarters
ACHL
56
DELISTED
Achilles Therapeutics
ACHL
$1.83M 0.13%
1,608,089
– –
2021 Q1
15 quarters
XERS icon
57
Xeris Biopharma Holdings
XERS
$1.84B
$1.53M 0.11%
451,099
-595,488
-57% -$1.92M
2018 Q2
26 quarters
IVVD icon
58
Invivyd
IVVD
$197M
$1.33M 0.09%
3,012,254
-53,460
-2% -$41.6K
2021 Q3
13 quarters
KLRS icon
59
Kalaris Therapeutics
KLRS
$52.1M
$801K 0.06%
82,955
– –
2020 Q3
17 quarters
ADAP
60
DELISTED
Adaptimmune Therapeutics
ADAP
$385K 0.03%
715,607
– –
2023 Q2
6 quarters
VTYX icon
61
DELISTED
Ventyx Biosciences
VTYX
$272K 0.02%
124,178
-1,983,037
-94% -$4.49M
2022 Q3
9 quarters
HOOK icon
62
DELISTED
HOOKIPA Pharma
HOOK
$214K 0.01%
106,376
– –
2019 Q2
22 quarters
CABA icon
63
Cabaletta Bio
CABA
$263M
– –
-442,826
Closed -$2.09M –
CTLT icon
64
DELISTED
CATALENT, INC.
CTLT
– –
-595,570
Closed -$36.1M –
GRTS icon
65
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-4,920,178
Closed -$2.85M –
AUGX icon
66
DELISTED
Augmedix, Inc. Common Stock
AUGX
– –
-16,380,327
Closed -$38.5M –
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2024 Portfolio in Review

As of Q4 2024, Redmile Group held 66 positions worth $1.43B, down 15% from $1.7B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group withdrew a net $141M in Q4 2024, closing 4 positions and reducing 40 holdings. Its most notable exit was Augmedix, Inc. Common Stock, an estimated $38.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in CeriBell Inc worth $11.3M.

  • Redmile Group's largest Q4 2024 buy was CeriBell Inc: 435,239 shares worth $11.3M.
  • Redmile Group added most to Neurogene in Q4 2024, an estimated $13.2M increase.
  • Redmile Group's biggest Q4 2024 reduction was Scholar Rock, cutting an estimated $22.4M.
  • Redmile Group fully exited Augmedix, Inc. Common Stock in Q4 2024, selling an estimated $38.5M.
  • Redmile Group's ten largest holdings make up 55% of its $1.43B portfolio in Q4 2024.
  • Redmile Group opened 3 new positions and closed 4 in Q4 2024.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $1.43B.

Based on Redmile Group's 13F filing for Q4 2024, filed 14 Feb 2025.